BSGM Stock Overview A medical technology company, focuses on deciphering the body’s electrical signals starting with heart rhythms. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
BioSig Technologies, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BioSig Technologies Historical stock prices Current Share Price US$0.89 52 Week High US$2.98 52 Week Low US$0.20 Beta 0.56 1 Month Change -38.47% 3 Month Change -49.37% 1 Year Change 15.56% 3 Year Change -94.25% 5 Year Change -97.90% Change since IPO -98.90%
Recent News & Updates BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $8.5 million. Dec 19
BioSig Technologies, Inc., Annual General Meeting, Dec 31, 2024 Nov 11
BioSig Technologies' Common Stock Deleted from OTC Equity Oct 25 Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million. BioSig Technologies, Inc. announced delayed 10-Q filing May 18
See more updates BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $8.5 million. Dec 19
BioSig Technologies, Inc., Annual General Meeting, Dec 31, 2024 Nov 11
BioSig Technologies' Common Stock Deleted from OTC Equity Oct 25 Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million. BioSig Technologies, Inc. announced delayed 10-Q filing May 18
BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2) May 08
BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer Apr 30 BioSig Technologies, Inc. announced delayed annual 10-K filing Apr 03
BioSig Technologies Receives Letter from Nasdaq Regarding No Longer Meets the Requirement of Rule 5550(b)(2) Mar 19
BioSig Technologies Receives a Letter from the Listing Qualifications Department of Nasdaq Stating That the Company Has Not Regained Compliance with the Rule Mar 12 Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer
BioSig Announces Reduction of its Workforce Feb 21 Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees BioSig Technologies, Inc. announced that it expects to receive $1.04 million in funding Jan 13
BioSig Technologies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Market Value of Listed Securities Dec 24
Consensus revenue estimates decrease by 67%, EPS upgraded Dec 19
Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now Dec 12
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16 BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million. Nov 15
BioSig Technologies, Inc. has filed a Follow-on Equity Offering. Nov 11
BioSig Technologies, Inc. has filed a Follow-on Equity Offering. Nov 10
Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President Nov 08
BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023 Nov 04 BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.13464 million. Nov 03
BioSig Technologies, Inc. announced that it has received $0.597497 million in funding Oct 26
Price target increased by 27% to US$5.63 Sep 15
Consensus revenue estimates decrease by 24% Sep 15 BioSig Technologies, Inc. announced that it has received $0.549999 million in funding
BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals Aug 25
Biosig Technologies, Inc. Introduces New Subscription Model for Pure Ep™ Platform, Offering Quicker Access to Latest Features, Customers Aug 24
Biosig Technologies, Inc.'s Pure Ep Platform Debuts New Automated Features in First Patient Cases Aug 23
Second quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022) Aug 16
New minor risk - Share price stability Jul 23
BioSig Technologies, Inc. Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare Jun 28
Price target increased by 8.0% to US$4.50 Jun 03
Consensus EPS estimates fall by 24% Jun 01
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 17
Consensus revenue estimates decrease by 65%, EPS upgraded Apr 11
BioSig Technologies, Inc. Announces Chief Financial Officer Changes Feb 08 BioSig Technologies, Inc. announced that it has received $1.299999 million in funding Feb 01
BioSig Technologies, Inc. announced that it expects to receive $0.159998 million in funding BioSig Technologies, Inc. announced that it expects to receive $1.299999 million in funding Jan 25
BioSig's PURE EP(TM) System Demonstrates Potential Time and Cost Savings At the 15th APHRS Scientific Session in Singapore Dec 15
Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why Dec 14
BioSig Technologies Receives a Letter from the Nasdaq Stock Market Nov 30
Consensus forecasts updated Nov 21
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 16
Price target decreased to US$4.17 Nov 16
BioSig Technologies, Inc., Annual General Meeting, Dec 20, 2022 Nov 08
BioSig Technologies Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Oct 27
BioSig in acquisition pact with San Antonio Hospital for cardiac signal system Oct 07
BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module Sep 23
BioSig: No Changes To Hold Thesis Following Q2 Earnings Sep 08
Consensus forecasts updated Aug 22
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 17
BioSig Technologies Receives Non-Compliance Letter from Nasdaq Jul 16
Consensus revenue estimates fall by 55% Jul 09
BioSig signs purchase deal with Kansas City's Overland Park Regional hospital Jul 07
BioSig: PURE EP Economics Trade Exhausted Jun 14
BioSig Technologies, Inc.’s PURE EP™ System to be Featured During EPLive 2022 May 26
Consensus revenue estimates fall by 18% May 24 Shareholder Returns BSGM US Medical Equipment US Market 7D -16.4% -0.2% 0.2% 1Y 15.6% 14.4% 23.1%
See full shareholder returns
Return vs Market: BSGM underperformed the US Market which returned 21% over the past year.
Price Volatility Is BSGM's price volatile compared to industry and market? BSGM volatility BSGM Average Weekly Movement 21.7% Medical Equipment Industry Average Movement 8.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: BSGM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BSGM's weekly volatility has decreased from 33% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body’s electrical signals starting with heart rhythms. It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The company’s product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
Show more BioSig Technologies, Inc. Fundamentals Summary How do BioSig Technologies's earnings and revenue compare to its market cap? BSGM fundamental statistics Market cap US$15.10m Earnings (TTM ) -US$15.45m Revenue (TTM ) US$39.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BSGM income statement (TTM ) Revenue US$39.00k Cost of Revenue US$0 Gross Profit US$39.00k Other Expenses US$15.49m Earnings -US$15.45m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.90 Gross Margin 100.00% Net Profit Margin -39,605.13% Debt/Equity Ratio 0%
How did BSGM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 10:45 End of Day Share Price 2025/02/11 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources BioSig Technologies, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Scott Henry Roth Capital Partners
